A British Journal of Cancer analysis reported that the timing of immune checkpoint inhibitor dosing can be associated with meaningful differences in overall survival for patients with advanced cancer. Rather than treating immunotherapy effectiveness as a single on/off variable, the study evaluated outcomes in relation to when treatment was administered. The work draws on a large, single-centre cohort and reframes clinical trial and real-world monitoring questions toward scheduling and sequence effects. While causality cannot be established from an observational design, the findings support further investigation of how dose timing interacts with tumor and host dynamics. For clinicians and trial designers, the results add a new variable to consider when comparing protocols that otherwise share similar drugs and response metrics.